進行再発肺がん・乳がんに対する腫瘍抗原MUC-1を標的とした樹状細胞ワクチン療法(<特集>がん疾患とアフェレシス)

概要

論文の詳細を見る
In this report, we described the MUC-1-tageting dendritic cell-based vaccine immunotherapy for patients with lung or breast cancers. MUC-1, a tumor antigen, has been considered to possess a strong immunogenicity and express itself in lung and breast cancers abundantly. The dendritic cells prepared from peripheral blood mononuclear cells, which were collected by apheresis, were pulsed with MUC-1 peptide, and subsequently administered to the patients. The vaccinations were repeated bi-weekly. Forty-six patients consisting of 29 lung and 17 breast cancer patients were treated with the vaccines and its effects evaluated. The effects of the vaccines were as follows: CR: PR: SD: PD: others=1: 2: 18: 18: 7 cases. The overall response (CR+PR) rate was 7.7% and the rate including CR, PR and SD was 53.8%. As undesirable side effects, neck pain, redness at vaccination sites and chill/fever were observed in 1, 4 and 10 cases, respectively. This dendritic cell-based vaccine may possess an ability to make the progressive tumors stable at a high frequency.
日本アフェレシス学会の論文
2009-05-31